Alcohol Misuse: A Risk Factor for Putaminal Damage by Ischemic Brain Infarct?

2003 ◽  
Vol 50 (2) ◽  
pp. 69-72 ◽  
Author(s):  
A. Leppävuori ◽  
R. Vataja ◽  
T. Pohjasvaara ◽  
M. Kaste ◽  
R. Mäntylä ◽  
...  
1992 ◽  
Vol 86 (5) ◽  
pp. 450-454 ◽  
Author(s):  
N. Heye ◽  
C. Paetzold ◽  
R. Steinberg ◽  
J. Cervos-Navarro

2012 ◽  
Vol 2012 ◽  
pp. 1-3
Author(s):  
Aliki Tympa ◽  
Dimitrios Hassiakos ◽  
Nikolaos Salakos ◽  
Aikaterini Melemeni

Administering neuraxial anesthesia to a patient with an underlying neurological disease and a combination of four other pathological disorders can be challenging. We report in this paper the case of a 45-year-old woman with neurological deficit due to ischemic brain infarct, multiple sclerosis, antiphospholipid syndrome, andβ-heterozygous thalassemia that was subjected to abdominal hysterectomy and bilateral salpingoophorectomy under epidural anesthesia for ovarian cancer.


2012 ◽  
Vol 40 (9) ◽  
pp. 607-610 ◽  
Author(s):  
Ivan Ivanov ◽  
Dora Zlatareva ◽  
Iliyana Pacheva ◽  
Margarita Panova

Stroke ◽  
2019 ◽  
Vol 50 (Suppl_1) ◽  
Author(s):  
Ken Chang ◽  
James Brown ◽  
Andrew Beers ◽  
Bruce Rosen ◽  
Jayashree Kalpathy-Cramer ◽  
...  

1984 ◽  
Vol 12 (4) ◽  
pp. 229-231 ◽  
Author(s):  
Gregg S. Nanni ◽  
Juri V. Kaude ◽  
John D. Reeder

Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 737 ◽  
Author(s):  
Jiun-Wen Guo ◽  
Chih-Cheng Chien ◽  
Jiann-Hwa Chen

Magnolol, which is a CYP3A substrate, is a well-known agent that can facilitate neuroprotection and reduce ischemic brain damage. However, a well-controlled release formulation is needed for the effective delivery of magnolol due to its poor water solubility. In this study, we have developed a formulation for a CYP3A-excipient microemulsion, which can be administrated intraperitoneally to increase the solubility and bioavailability of magnolol and increase its neuroprotective effect against ischemic brain injury. The results showed a significant improvement in the area under the plotted curve of drug concentration versus time curve (AUC0–t) and mean residence time (MRT) of magnolol in microemulsion compared to when it was dissolved in dimethyl sulfoxide (DMSO). Both magnolol in DMSO and microemulsion, administrated after the onset of ischemia, showed a reduced visual brain infarct size. As such, this demonstrates a therapeutic effect on ischemic brain injury caused by occlusion, however it is important to note that a pharmacological effect cannot be concluded by this study. Ultimately, our study suggests that the excipient inhibitor-based microemulsion formulation could be a promising concept for the substrate drugs of CYP3A.


1996 ◽  
Vol 169 (4) ◽  
pp. 434-439 ◽  
Author(s):  
Alexander J. Bremner ◽  
Peter J. Duke ◽  
Hazel E. Nelson ◽  
Christos Pantelis ◽  
Thomas R. E. Barnes

BackgroundFour previous studies of homeless adults have yielded conflicting results regarding the presence of cognitive impairment.MethodA consecutive series of 80 roofless entrants to a hostel for homeless men were sampled and 62 (76%) completed a range of assessments, including measures of mental state, cognitive functions and substance use.ResultsEstimated premorbid IQ (mean=96), current IQ (mean=84) and cognitive speed were significantly lower than the norm. There was a significant IQ drop in all diagnostic groups. IQ drop, but not current IQ, correlated with duration of rooflessness. Those with schizophrenia or alcohol problems were roofless for longest. Alcohol misuse did not correlate with IQ drop, excepting alcohol withdrawal symptoms in those with schizophrenia.ConclusionThe hypothesis that low IQ is a risk factor for rooflessness is supported. However, length of rooflessness was more closely related to IQ drop than to current IQ, suggesting that some third factor may be affecting both rooflessness and intellectual functioning. Roofless men with schizophrenia or alcohol problems may be especially at risk of long-term rooflessness.


2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Seung Hee Kim ◽  
Ki Young Son

Abstract Background Dyslipidemia is considered an independent health risk factor of cardiovascular disease (CVD), a leading cause of mortality in older adults. Despite its importance, there have been few reports on the association between lipoprotein cholesterol and future CVD and cardiovascular (CV) mortality among elderly Asians aged ≥ 65 years. This study investigated the association between lipoprotein cholesterol and future CVD and CV mortality in an elderly Korean population using a large nationwide sample. Methods From the cohort database of the Korean National Health Insurance Service, 62,604 adults aged ≥ 65 years (32,584 men and 30,020 women) were included. High-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were categorized by quartiles. Cox proportional hazard models and linear regression analyses were used to assess the association between the quartiles of lipoprotein cholesterol and future CV events or mortality. Results The mean follow-up period was 3.3 years. The incidence rates of ischemic heart disease and ischemic brain disease were 0.97 and 0.61 per 1,000 person-years, respectively, and the mortality rates from these diseases were 0.22 and 0.34 per 1,000 person-years, respectively. In a completely adjusted model, high HDL-C and LDL-C levels were not associated with total CV events and CVD mortality. However, high LDL-C levels were significantly associated with a lower incidence of ischemic brain disease. Furthermore, diabetic patients with high LDL-C levels were more likely to have higher CV mortality, whereas non-smokers with high LDL-C levels were less likely to be at risk of CV events. Conclusions Neither high LDL-C nor HDL-C levels were significantly associated with future CV mortality in older adults aged ≥ 65 years. High LDL-C levels do not seem to be a risk factor for CVD in elderly individuals, and further studies are required.


Sign in / Sign up

Export Citation Format

Share Document